<?xml version="1.0" encoding="UTF-8"?>
<p id="par0180">A preliminary Brazilian randomized, double-blinded, clinical trial has investigated two different CQ dosages (600 mg twice daily for 10 days vs. 450 mg for 5 days, twice daily only on the first day) in 81 patients with severe COVID-19. All patients received ceftriaxone and azithromycin as well. The high dosage CQ arm had higher QTc prolongation and mortality rates, with no apparent benefit of CQ regarding viral clearance or mortality in either study arms [
 <xref rid="bib0305" ref-type="bibr">61</xref>]. Of note, only 62 out of the enrolled 81 patients had been confirmed by RT-PCR.
</p>
